142 related articles for article (PubMed ID: 10551714)
1. European multicenter study on propionyl-L-carnitine in intermittent claudication.
Brevetti G; Diehm C; Lambert D
J Am Coll Cardiol; 1999 Nov; 34(5):1618-24. PubMed ID: 10551714
[TBL] [Abstract][Full Text] [Related]
2. Effect of propionyl-L-carnitine on quality of life in intermittent claudication.
Brevetti G; Perna S; Sabba C; Martone VD; Di Iorio A; Barletta G
Am J Cardiol; 1997 Mar; 79(6):777-80. PubMed ID: 9070558
[TBL] [Abstract][Full Text] [Related]
3. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
Brevetti G; Perna S; Sabbá C; Martone VD; Condorelli M
J Am Coll Cardiol; 1995 Nov; 26(6):1411-6. PubMed ID: 7594063
[TBL] [Abstract][Full Text] [Related]
4. Propionyl-L-carnitine for intermittent claudication.
Kamoen V; Vander Stichele R; Campens L; De Bacquer D; Van Bortel L; de Backer TL
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD010117. PubMed ID: 34954832
[TBL] [Abstract][Full Text] [Related]
5. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.
Hiatt WR; Regensteiner JG; Creager MA; Hirsch AT; Cooke JP; Olin JW; Gorbunov GN; Isner J; Lukjanov YV; Tsitsiashvili MS; Zabelskaya TF; Amato A
Am J Med; 2001 Jun; 110(8):616-22. PubMed ID: 11382369
[TBL] [Abstract][Full Text] [Related]
6. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication.
Delaney CL; Spark JI; Thomas J; Wong YT; Chan LT; Miller MD
Atherosclerosis; 2013 Jul; 229(1):1-9. PubMed ID: 23557982
[TBL] [Abstract][Full Text] [Related]
7. Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication.
Strano A
Clin Drug Investig; 2002 Nov; 22(Suppl 1):1-6. PubMed ID: 23315429
[TBL] [Abstract][Full Text] [Related]
8. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
Hiatt WR; Creager MA; Amato A; Brass EP
J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
[TBL] [Abstract][Full Text] [Related]
9. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
[TBL] [Abstract][Full Text] [Related]
10. Propionyl-L-carnitine.
Wiseman LR; Brogden RN
Drugs Aging; 1998 Mar; 12(3):243-8; discussion 249-50. PubMed ID: 9534023
[TBL] [Abstract][Full Text] [Related]
11. Carnitine and peripheral arterial disease.
Hiatt WR
Ann N Y Acad Sci; 2004 Nov; 1033():92-8. PubMed ID: 15591006
[TBL] [Abstract][Full Text] [Related]
12. New treatment options in intermittent claudication: the US experience.
Hiatt WR
Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
[TBL] [Abstract][Full Text] [Related]
13. Study on propionyl-L-carnitine in chronic heart failure.
Eur Heart J; 1999 Jan; 20(1):70-6. PubMed ID: 10075143
[TBL] [Abstract][Full Text] [Related]
14. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
Dal Lago A; De Martini D; Flore R; Gaetani E; Gasbarrini A; Gerardino L; Pola R; Santoliquido A; Serricchio M; Tondi P; Nolfe G
Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
[TBL] [Abstract][Full Text] [Related]
15. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
Andreozzi GM
Expert Opin Pharmacother; 2009 Nov; 10(16):2697-707. PubMed ID: 19827991
[TBL] [Abstract][Full Text] [Related]
16. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease.
Barker GA; Green S; Askew CD; Green AA; Walker PJ
Med Sci Sports Exerc; 2001 Sep; 33(9):1415-22. PubMed ID: 11528327
[TBL] [Abstract][Full Text] [Related]
17. Propionyl-L-carnitine for intermittent claudication.
Deckert J
J Fam Pract; 1997 Jun; 44(6):533-4. PubMed ID: 9191622
[No Abstract] [Full Text] [Related]
18. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study.
Brevetti G; Perna S; Sabbà C; Rossini A; Scotto di Uccio V; Berardi E; Godi L
Eur Heart J; 1992 Feb; 13(2):251-5. PubMed ID: 1555624
[TBL] [Abstract][Full Text] [Related]
19. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
20. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
Dawson DL; Cutler BS; Meissner MH; Strandness DE
Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
